<DOC>
	<DOCNO>NCT00800735</DOCNO>
	<brief_summary>This single arm study provide treatment re-treatment PEGASYS monotherapy combination ribavirin ( Copegus ) , patient chronic hepatitis C ( CHC ) participate previous Roche Roche partner protocol access treatment re-treatment promise deem appropriate follow completion original protocol ( 'donor ' protocol ) . Patients qualify treatment re-treatment begin PEGASYS monotherapy , maximum dose 180 µg weekly , combination therapy Copegus , 800-1200 mg daily , continuation treatment wash-out period define donor protocol . PEGASYS treatment exceed approve treatment duration 48 week genotype G1 treatment-free follow period 24 week .</brief_summary>
	<brief_title>A Study PEGASYS ( Pegylated-interferon Alfa-2a ) With Without Ribavirin Patients With Chronic Hepatitis C Who Have Participated Previous Roche Roche Partner Protocols</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Adult patient , ≥ 18 year age . Chronic hepatitis C ( CHC ) patient compensate liver disease ( ChildPugh A ) participate donor protocol access treatment retreatment PEGASYS monotherapy combination Copegus promise deem appropriate completion donor protocol . Evidence decompensated liver disease ( Child B C cirrhosis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>